Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
· The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technology · The agreement may be extended into an exclusive commercial partnership for KRAS vaccination if the combination proves effective in exploratory clinical studiesOslo, Norway, 07 March 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, and Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint